Menarini Korea is the Korean subsidiary of the Menarini Group in Italy which has a history of 129 years and was officially established on March 1, 2013.
Menarini Korea strives to carry out its mission of contributing to the Korean society to enable Koreans to enjoy a happier and healthier life. To this end, Menarini Korea strengthened its core businesses such as cardiovascular diseases, men’s health, tumors/special diseases, allergies/respiratory diseases, etc. along with the dermatology field and consumer health areas.
As a result, Menarini Korea now directly supplies its products that used to be distributed through certain partnering distributors and will show off various new products in the future. With “Nebilet”, a vasodilating beta-blocker, and “Zofenil”, an ACE inhibitor, at the forefront, Menarini Korea also launched “Priligy”, the world’s first oral medication for the treatment of premature ejaculation, and “Keral”, a pain killer. The officers and employees of Menarini Korea have gathered together with the grand dream of further developing the company and making social contributions and the will to realize such dream.